Idiopathic Pulmonary Fibrosis (IPF) is a frightening, incurable disease where the lungs become increasingly damaged by scar tissue, resulting in breathing getting progressively more difficu
A new project has been launched to develop artificial intelligence models that more closely reflect the diversity seen in patients with lung disease in the UK.
Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised
Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim's Ofev, following new guidance from health technology assess
Swedish digital health company Alex Therapeutics has reported encouraging results in a trial of a digital therapeutic (DTx) for anxiety in patients with the respiratory disease idiopathic p
Two additional novel AI-generated targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) have been discovered using the Benevolent Platform and selected for AstraZ
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl